Pedro Alvarez1, Luiz F Ferrari, Jon D Levine. 1. Department of Oral and Maxillofacial Surgery, University of California, San Francisco, San Francisco, CA 94143-0440, USA.
Abstract
OBJECTIVE: While inflammatory pain is well described in skeletal muscle, neuropathic muscle pain remains to be clarified. We used 3 well-established rodent models of peripheral neuropathy to evaluate for muscle pain. METHODS: In rats exposed to either of 2 neurotoxic cancer chemotherapies, paclitaxel or oxaliplatin, or to alcohol consumption, we assessed the evolution of mechanical hyperalgesia in skeletal muscle and skin, in the same animal. To explore the involvement of protein kinase C epsilon (PKCε), a second messenger implicated in some forms of neuropathic pain, antisense oligodeoxynucleotides (AS-ODNs) or mismatch ODNs (MM-ODNs) for PKCε were administered intrathecally. RESULTS: Rats submitted to models of chemotherapy-induced and alcohol-induced neuropathy developed persistent muscle hyperalgesia, which evolved in parallel in muscle and skin. The administration of PKCε AS, which has been shown to mediate cutaneous hyperalgesia in paclitaxel and ethanol models of neuropathic pain, also inhibited muscle hyperalgesia induced by these agents. Stopping AS-ODN was associated with the reappearance of hyperalgesia at both sites. The AS-ODN to PKCε treatment was devoid of effect in both muscle and skin in the oxaliplatin neuropathy model. INTERPRETATION: Our results support the suggestion that neuropathic muscle pain may be a greater clinical problem than generally appreciated.
OBJECTIVE: While inflammatory pain is well described in skeletal muscle, neuropathic muscle pain remains to be clarified. We used 3 well-established rodent models of peripheral neuropathy to evaluate for muscle pain. METHODS: In rats exposed to either of 2 neurotoxic cancer chemotherapies, paclitaxel or oxaliplatin, or to alcohol consumption, we assessed the evolution of mechanical hyperalgesia in skeletal muscle and skin, in the same animal. To explore the involvement of protein kinase C epsilon (PKCε), a second messenger implicated in some forms of neuropathic pain, antisense oligodeoxynucleotides (AS-ODNs) or mismatch ODNs (MM-ODNs) for PKCε were administered intrathecally. RESULTS:Rats submitted to models of chemotherapy-induced and alcohol-induced neuropathy developed persistent muscle hyperalgesia, which evolved in parallel in muscle and skin. The administration of PKCε AS, which has been shown to mediate cutaneous hyperalgesia in paclitaxel and ethanol models of neuropathic pain, also inhibited muscle hyperalgesia induced by these agents. Stopping AS-ODN was associated with the reappearance of hyperalgesia at both sites. The AS-ODN to PKCε treatment was devoid of effect in both muscle and skin in the oxaliplatinneuropathy model. INTERPRETATION: Our results support the suggestion that neuropathic muscle pain may be a greater clinical problem than generally appreciated.
Authors: A Y Bedikian; C Plager; J R Stewart; C A O'Brian; S K Herdman; M Ross; N Papadopoulos; O Eton; J Ellerhorst; T Smith Journal: Melanoma Res Date: 2001-04 Impact factor: 3.599
Authors: Gretha van de Glind; Maaike de Vries; Richard Rodenburg; Frans Hol; Jan Smeitink; Eva Morava Journal: Eur J Paediatr Neurol Date: 2007-02-12 Impact factor: 3.140
Authors: Susanna B Park; Cindy S-Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan Journal: Brain Date: 2009-09-10 Impact factor: 13.501
Authors: Paul A Glare; Pamela S Davies; Esmé Finlay; Amitabh Gulati; Dawn Lemanne; Natalie Moryl; Kevin C Oeffinger; Judith A Paice; Michael D Stubblefield; Karen L Syrjala Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Xiaowei Zang; Jong Bong Lee; Kiran Deshpande; Olga B Garbuzenko; Tamara Minko; Leonid Kagan Journal: J Control Release Date: 2019-04-11 Impact factor: 9.776
Authors: Laura E Simons; Eric A Moulton; Clas Linnman; Elizabeth Carpino; Lino Becerra; David Borsook Journal: Hum Brain Mapp Date: 2012-10-25 Impact factor: 5.038